Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
Veterans Affairs hospitals adopted more infection prevention practices than non-VA hospitals.
Healthcare workers were more likely to partake in hand-hygiene protocols after contaminating tasks vs critical tasks and before such tasks.
Rates of hospitalizations for serious bacterial infections among people with substance use disease are increasing, especially in younger populations.
Eradication of prosthetic hip and knee joint infections is challenging, with failure rates >20% even in the setting of complete prosthesis removal.
Infection prevention programs targeting low-income groups undergoing colectomy may be important in reducing surgical site infections.
Recent reports present updated summaries of common pathogens and antimicrobial resistance patterns among health care-associated infections.
There is a need to improve infectious risk mitigation in adults with diabetes because they are hospitalized for infections between 2.6 and 15.7 times as often as adults without diabetes, depending on the type of infection.
Among individuals with acute myelogenous leukemia (AML), carbapenem-nonsusceptible gram-negative bacteremia (GNB) is associated with worse outcomes than carbapenem-susceptible GNB.
A closed ICU model is associated with a reduction in certain types of hospital-acquired infections.
